In this study, betaine intake will be increased in formula-fed infants through formula milk supplementation. To do this, a double-blind randomized study has been designed with the supplementation group (infant formula supplemented with betaine) and control group (unsupplemented infant formula). The main objectives of the study are to determine the safety of supplementation and to assess whether there are changes in infant growth.
Childhood obesity is one of the main public health concerns worldwide. Previous results have linked a nutrient called betaine (trimethylglycine) to the risk of childhood obesity. Betaine is a modified amino acid with osmotic properties that participates in the methionine cycle as a methyl group donor. Specifically, previous data demonstrate a link between breast milk betaine content, postnatal growth, and long-term metabolic health, suggesting that betaine supplementation may be an effective strategy for regulating growth trajectories and preventing childhood obesity. This study will assess the effects of increasing betaine intake in formula-fed infants through formula milk supplementation. To do this, a double-blind randomized study has been designed where participants will be randomly assigned to the control group or the supplementation group. The main objectives of the study are to determine the safety of supplementation and to assess whether there are changes in infant growth. Additionally, potential changes in the intestinal microbiome induced by the increase in betaine intake will be analyzed.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
50
Infant formula will be supplemented with betaine to provide a final concentration of 100 µmol/L in the reconstituted milk. The intervention will last for 12 weeks.
Regular (unmodified) infant formula . The intervention will last for 12 weeks.
Hospital Sant Joan de Déu
Barcelona, Barcelona, Spain
Change in weight-for-length z score
Weight and length will be measured at different time-points and combined to calculate weight-for-length z scores.
Time frame: From start to the end of treatment at 12 weeks and at 12 months of follow-up
Changes in fecal microbiota composition
Differences in features associated with a healthy mucosal layer and metabolic state (e.g. Bifidobacteria and Akkermansia relative amount). Stool samples will be processed to isolate the bacterial DNA. Microbiome composition will be determined by DNA sequencing.
Time frame: At 4 weeks and 12 weeks end of treatment, and at 12 months of follow-up
Infant body composition
Total body and abdominal fat mass measured by dual energy x-ray absorptiometry (DXA) scan
Time frame: At 12 months of follow-up
Urine one-carbon metabolite concentration
Urine samples will be analyzed to quantify betaine content as well as related metabolites (including dimethylglycine, the product of the betaine demethylation reaction
Time frame: At 4 weeks and 12 weeks after start of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.